Thommen Chacko
About Thommen Chacko
Thommen Chacko is the Vice President of US & WW Commercial Strategy, Performance & Forecasting at Bristol-Myers Squibb in Princeton, New Jersey. He has extensive experience in oncology forecasting, strategic planning, and healthcare data analytics.
Title
Thommen Chacko holds the position of Vice President, US & WW Commercial Strategy, Performance & Forecasting at Bristol-Myers Squibb. In this role, based in Princeton, New Jersey, he is responsible for leading the global commercial strategy, performance analysis, and forecasting operations.
Professional Background
Thommen Chacko's career spans various roles within the pharmaceutical industry. He has served Bristol-Myers Squibb in numerous capacities, including Director, WW Oncology Forecasting & Strategic Planning in Princeton, NJ (2018-2020), Director, Oncology Business Insights & Analytics in Munich, Germany (2016-2018), Director, US Oncology Forecasting in Princeton, NJ (2014-2016), and Associate Director, US Forecasting in Princeton, NJ (2013-2014). He has also held roles at IMS Health as a Consultant and Analyst, and at PharmARC Inc. and PharmARC Analytic Solutions.
Education and Expertise
Thommen Chacko studied Biotechnology Management at SIES College of Management Studies and achieved a Post Graduate Diploma in Management (PGDM) from 2008 to 2010. His academic background laid a solid foundation for his career in pharmaceutical forecasting, strategic planning, and business analytics.
Career in Pharmaceutical Industry
Thommen Chacko began his career in the pharmaceutical industry with a summer internship at Panacea Biotech in 2009. He then held various analytical and consulting roles at PharmARC Analytic Solutions and IMS Health. At Bristol-Myers Squibb, he has transitioned through progressively senior roles, gaining extensive experience in oncology forecasting and strategic business insights.
Global Strategic Roles
Throughout his career, Thommen Chacko has demonstrated a capacity for leadership in global strategic roles. Notably, he led the WW Oncology Forecasting & Strategic Planning team at Bristol-Myers Squibb, contributing significantly to global oncology strategy. His progression from US-focused roles to broader WW responsibilities showcases his expanding expertise and leadership capabilities.